FAIR Labels Act of 2026

1) On April 30, 2026, Sen. Ricketts (R-NE) introduced S.4464, the FAIR Labels Act of 2026, which was read twice and referred to the Committee on Agriculture, Nutrition, and Forestry. The bill is in the earliest legislative stage with only two actions (introduction and referral). It has one cosponsor (Sen. Fetterman) and an identical companion bill in the House (HR8596). 2) The bill does not authorize or appropriate any funding. Its sole mechanism is to require the Secretaries of Agriculture and Health and Human Services to revise a 2019 MOU regarding oversight of cell-cultivated protein products. The bill assigns specific regulatory responsibilities to FDA (premarket consultation, cell bank oversight, inspections) and USDA (implementation of labeling amendments). No money flows to any private entity. 3) Structural winners and losers: This bill is purely procedural and regulatory. It does not change demand for traditional meat, poultry, or agricultural inputs. Companies like Deere, CF Industries, Corteva, Bunge, Archer-Daniels-Midland, FMC, and Mosaic face zero direct revenue impact. The bill's labeling requirements could eventually affect cell-cultivated protein producers (e.g., Upside Foods, Eat Just, GOOD Meat — none publicly traded), but the bill is too early-stage to assess. No publicly traded pure-play cell-cultivated meat companies exist on US exchanges. 4) No real market data is provided for stock prices. The competitive landscape for traditional agriculture remains unchanged by this bill. 5) Timeline: The bill must pass the Senate Agriculture Committee, then the full Senate, then the House (where HR8596 is pending in Agriculture and Energy & Commerce committees), then be signed by the President. Given the early stage and lack of committee markup, passage in the 119th Congress is uncertain. The 90-day implementation timeline after enactment is irrelevant until passage.